- Home
- Publications
- Publication Search
- Publication Details
Title
MET in gastric cancer - discarding a 10% cutoff rule
Authors
Keywords
-
Journal
HISTOPATHOLOGY
Volume 68, Issue 2, Pages 241-253
Publisher
Wiley
Online
2015-05-28
DOI
10.1111/his.12745
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development
- (2015) Stephen P. Hack et al. Oncotarget
- MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
- (2015) Denis L. Fontes Jardim et al. Oncotarget
- Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer
- (2014) Yukinori Kurokawa et al. ANNALS OF SURGICAL ONCOLOGY
- HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
- (2014) Y J Liu et al. BRITISH JOURNAL OF CANCER
- Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma
- (2014) Akiko Kawano Nagatsuma et al. Gastric Cancer
- HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy
- (2014) Sang Yun Ha et al. INTERNATIONAL JOURNAL OF CANCER
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
- (2014) Kai Wang et al. NATURE GENETICS
- Targeting receptor tyrosine kinases in gastric cancer
- (2014) Asahiro Morishita WORLD JOURNAL OF GASTROENTEROLOGY
- Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule
- (2014) Hans-Michael Behrens et al. Cancer Medicine
- Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study
- (2013) S. Watson et al. ANNALS OF ONCOLOGY
- Expression of MACC1 and c-Met in human gastric cancer and its clinical significance
- (2013) Tiankang Guo et al. Cancer Cell International
- Prognostic and Putative Predictive Biomarkers of Gastric Cancer for Personalized Medicine
- (2013) Viktoria S. Warneke et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
- (2013) Yoon-Koo Kang et al. INVESTIGATIONAL NEW DRUGS
- MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas
- (2013) Sang Y Ha et al. MODERN PATHOLOGY
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation
- (2013) Guy Betts et al. VIRCHOWS ARCHIV
- MET: A Critical Player in Tumorigenesis and Therapeutic Target
- (2013) C. R. Graveel et al. Cold Spring Harbor Perspectives in Biology
- Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
- (2012) V. S. Warneke et al. ANNALS OF ONCOLOGY
- MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
- (2012) H E Lee et al. BRITISH JOURNAL OF CANCER
- A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
- (2012) Niantao Deng et al. GUT
- Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma
- (2012) Yin Li et al. JOURNAL OF SURGICAL ONCOLOGY
- RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
- (2011) Daniel V.T. Catenacci et al. CANCER BIOLOGY & THERAPY
- Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer
- (2011) Yuji Toiyama et al. INTERNATIONAL JOURNAL OF CANCER
- Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer
- (2011) Francesco Graziano et al. JOURNAL OF CLINICAL ONCOLOGY
- METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
- (2011) Jochen K. Lennerz et al. JOURNAL OF CLINICAL ONCOLOGY
- Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer
- (2010) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Mucin phenotype of gastric cancer and clinicopathology of gastric-type differentiated adenocarcinoma
- (2010) Tsutomu Namikawa WORLD JOURNAL OF GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now